Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.
暂无分享，去创建一个
A. Mead | C. Yap | A. Dueck | R. Mesa | N. Cross | M. McMullin | C. Harrison | N. Panoskaltsis | R. Scherber | S. Knapper | J. Coppell | E. Gbandi | A. Hamblin | J. Ewing | M. Wood | S. Alimam | Sonia Fox | A. Panchal | Frederick E Chen | Sahra Ali | A. Houlton | R. Scherber | Frederick Chen